ArticleFrontiers in medicine2025
Effect of afzelin on inflammation and lipogenesis in particulate matter-stimulated
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dissolvable silk microneedles delivering minocycline-loaded ZIF-8 nanoparticles for targeted modulation of sebocyte metabolism and improved acne therapy.Journal of nanobiotechnology · 2026Article
- Exposome involvement in the development of acne vulgaris.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Afzelin, a flavonoid (kaempferol 3-O-α-L-rhamnopyranoside) isolated from Objective: This study aimed to (i) investigate inflammatory and sebum secretion changes when a Methods: To investigate the effect of afzelin on PM- and Results: PM treatment upregulated the mRNA and protein expression levels of inflammatory cytokine and lipogenic genes in Conclusions: This study's findings indicate that PM potentially aggravates acne by acting on both inflammation and sebum secretion. They also reveal afzelin's ability to suppress these phenomena by not only suppressing inflammatory cytokine expression but also inhibiting sebogenesis. These findings confirm afzelin's potential therapeutic role in improving PM-exacerbated acne.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.